Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Pain Beliefs and Intracortical Excitability During Experimental Pain

torstai 2. heinäkuuta 2026 päivittänyt: Guillaume Léonard, Université de Sherbrooke

Influence Of Pain-Related Beliefs On The Modulation Of Intracortical Circuits During Experimental Pain Induced By Topical Capsaicin

Pain can influence the way the motor system functions. However, responses to pain vary widely between individuals, and this variability may be partly related to pain-related beliefs such as kinesiophobia.

This study examines whether temporary experimental pain changes intracortical excitability in the motor cortex, and whether this response differs according to baseline kinesiophobia. Healthy adults will complete one experimental session. Motor cortex excitability will first be assessed at baseline using transcranial magnetic stimulation, a non-invasive brain stimulation technique. A topical capsaicin cream will then be applied to the forearm to induce temporary, moderate experimental pain. Once pain is established, the same neurophysiological assessments will be repeated.

The main objective is to measure changes in short-interval intracortical inhibition before and during capsaicin-induced pain, with particular attention to whether these changes are associated with baseline kinesiophobia.

Secondary objectives are to characterize other markers of motor cortex excitability, including long-interval intracortical inhibition, short-interval intracortical facilitation, intracortical facilitation, and corticospinal excitability assessed using input-output recruitment curves. Pain intensity will be monitored using a visual analog scale to characterize the experimental pain response. Baseline kinesiophobia will be assessed using the Tampa Scale of Kinesiophobia and examined as a factor associated with interindividual variability in neurophysiological responses to experimental pain.

The researchers expect that changes in motor cortex excitability during experimental pain will vary between individuals, and that individuals with higher kinesiophobia may show smaller changes in motor cortex excitability during capsaicin-induced pain.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Pain is not only a sensory experience. It is also influenced by psychological, emotional, and contextual factors, including how people interpret pain and the threat they associate with movement. In the presence of pain, individuals often modify the way they move. These adaptations may be protective in the short term, but when maintained over time, they may contribute to persistent movement avoidance and disability.

Within the fear-avoidance framework, kinesiophobia, or fear of movement, is considered an important factor in the relationship between pain, movement, and disability. Individuals with higher kinesiophobia may perceive movement as threatening or potentially harmful. This may influence not only motor behavior, but also the way the nervous system prepares and controls movement. However, the neurophysiological mechanisms linking pain-related beliefs, experimental pain, and motor control remain incompletely understood.

The primary motor cortex is a key brain region involved in voluntary movement. Its excitability can be assessed using transcranial magnetic stimulation, a non-invasive brain stimulation technique. When applied over the primary motor cortex, transcranial magnetic stimulation can evoke motor responses that are recorded from a target muscle using surface electromyography. These responses provide information about corticospinal excitability and about intracortical inhibitory and facilitatory mechanisms.

Previous studies suggest that experimental pain can modify motor cortex excitability, but the direction and magnitude of these changes vary considerably between individuals. Pain-related beliefs, especially kinesiophobia, may partly explain this variability. This study therefore focuses on whether experimental pain changes intracortical excitability in the motor cortex and whether this response differs according to baseline kinesiophobia.

The main objective is to quantify changes in short-interval intracortical inhibition before and during experimental pain induced by topical capsaicin, with particular attention to whether these changes vary according to the participant's baseline level of kinesiophobia. Short-interval intracortical inhibition is used as the primary neurophysiological measure because it reflects inhibitory activity within the motor cortex.

Secondary objectives are to characterize other markers of motor cortex excitability during experimental pain. These include long-interval intracortical inhibition, intracortical facilitation, and corticospinal excitability assessed using input-output recruitment curves. These complementary measures are included to provide a broader characterization of inhibitory, facilitatory, and corticospinal responses to experimental pain.

Healthy adults will complete one experimental session. At the beginning of the session, participants will complete questionnaires assessing pain-related beliefs, including kinesiophobia. Baseline neurophysiological assessments will then be performed using transcranial magnetic stimulation applied over the primary motor cortex, with electromyographic recordings from the first dorsal interosseous muscle of the hand.

After baseline measurements, topical capsaicin cream will be applied to the forearm to induce temporary, moderate experimental pain. Pain intensity will be monitored using a visual analog scale. Once experimental pain is established, the same transcranial magnetic stimulation assessments will be repeated.

Each participant serves as their own control, with neurophysiological measures compared between the baseline condition and the experimental pain condition. The investigators hypothesize that changes in motor cortex excitability during experimental pain will vary between individuals. This variability is expected to be partly related to kinesiophobia, with individuals reporting higher kinesiophobia showing smaller changes in motor cortex excitability during capsaicin-induced pain.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

30

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

Opiskelupaikat

    • Quebec
      • Sherbrooke, Quebec, Kanada, J1H 5H3
        • Université de Sherbrooke - Campus de la santé
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:
        • Päätutkija:
          • Guillaume Léonard, Ph.D.

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen

Hyväksyy terveitä vapaaehtoisia

Joo

Kuvaus

Inclusion Criteria:

  • Aged 18 to 35 years, inclusive
  • Healthy
  • Able to understand the study information and experimental procedures
  • Able to provide informed consent

Exclusion Criteria:

  • History of psychiatric disorders (including intellectual disability or severe cognitive, behavioral, or affective impairment) that could interfere with understanding the study or providing informed consent.
  • History of neurological disorders, including epilepsy, stroke, brain or spinal cord surgery, or any neurological disease affecting motor or sensory function.

Inability to provide informed consent (e.g., dementia, significant hearing impairment, insufficient language proficiency).

  • Any pain condition within the past 3 months, regardless of origin.
  • Recent musculoskeletal injury or surgery within the past 3 months.
  • Contraindications to transcranial magnetic stimulation (TMS), including a history of epilepsy or the presence of intracranial metallic objects, cochlear implants, or other non-removable metallic implants in or near the head.
  • Use of analgesic or psychotropic medications.
  • Individuals under legal guardianship or curatorship.
  • Pregnant or breastfeeding women.
  • Presence of a cardiac pacemaker or other implanted electronic medical device.
  • Known allergy or previous skin reaction to capsaicin

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Perustiede
  • Jako: Ei käytössä
  • Inventiomalli: Yksittäinen ryhmätehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Experimental pain
Participants complete one experimental session. Motor cortex excitability is first assessed at baseline using transcranial magnetic stimulation with electromyographic recordings from the first dorsal interosseous muscle. Topical capsaicin cream is then applied to the forearm to induce temporary, moderate experimental pain. Once pain is established, the same neurophysiological assessments are repeated during the pain condition.
Topical capsaicin cream (1%) is applied to the forearm to induce temporary, moderate experimental pain. Motor cortex excitability is assessed before and during capsaicin-induced pain using transcranial magnetic stimulation.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in Short-Interval Intracortical Inhibition
Aikaikkuna: At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)
Short-interval intracortical inhibition will be assessed using paired-pulse transcranial magnetic stimulation over the primary motor cortex, with electromyographic recordings from the first dorsal interosseous muscle. A subthreshold conditioning stimulus set at 80% of resting motor threshold will be followed by a suprathreshold test stimulus set at 120% of resting motor threshold, with an interstimulus interval of 3 ms. Fifteen conditioned trials will be recorded for this measure. The outcome will be expressed as the change in conditioned motor evoked potential amplitude relative to the unconditioned test response from pre- to post-application of topical capsaicin cream.
At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in Short-Interval Intracortical Facilitation
Aikaikkuna: At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)
Short-interval intracortical facilitation will be assessed using paired-pulse transcranial magnetic stimulation over the primary motor cortex, with electromyographic recordings from the first dorsal interosseous muscle. A suprathreshold conditioning stimulus set at 120% of resting motor threshold will be followed by a subthreshold test stimulus set at 80% of resting motor threshold, with an interstimulus interval of 2 ms. Fifteen conditioned trials will be recorded for this measure. The outcome will be expressed as the change in conditioned motor evoked potential amplitude relative to the unconditioned test response from pre- to post-application of topical capsaicin cream.
At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)
Change in Pain Intensity
Aikaikkuna: From baseline through completion of the experimental session, an average of 2 hours
Pain intensity will be assessed using a visual analog scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. The outcome will be expressed as the change in pain intensity from pre- to post-application of topical capsaicin cream.
From baseline through completion of the experimental session, an average of 2 hours
Change in Intracortical Facilitation
Aikaikkuna: At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)
Intracortical facilitation will be assessed using paired-pulse transcranial magnetic stimulation over the primary motor cortex, with electromyographic recordings from the first dorsal interosseous muscle. A subthreshold conditioning stimulus set at 80% of resting motor threshold will be followed by a suprathreshold test stimulus set at 120% of resting motor threshold, with an interstimulus interval of 15 ms. Fifteen conditioned trials will be recorded for this measure. The outcome will be expressed as the change in conditioned motor evoked potential amplitude relative to the unconditioned test response from pre- to post-application of topical capsaicin cream.
At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)
Change in Long-Interval Intracortical Inhibition
Aikaikkuna: At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)
Long-interval intracortical inhibition will be assessed using paired-pulse transcranial magnetic stimulation over the primary motor cortex, with electromyographic recordings from the first dorsal interosseous muscle. A suprathreshold conditioning stimulus set at 120% of resting motor threshold will be followed by a suprathreshold test stimulus set at 120% of resting motor threshold, with an interstimulus interval of 100 ms. Fifteen conditioned trials will be recorded for this measure. The outcome will be expressed as the change in conditioned motor evoked potential amplitude relative to the unconditioned test response from pre- to post-application of topical capsaicin cream.
At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)
Change from baseline in corticospinal excitability
Aikaikkuna: At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)
Corticospinal excitability will be assessed using single-pulse transcranial magnetic stimulation applied over the primary motor cortex, with electromyographic recordings from the first dorsal interosseous muscle. Single magnetic pulses of increasing intensity will be delivered to construct input-output recruitment curves for each participant. Stimulation intensity will be increased in 5% steps, and 10 stimuli will be delivered at each intensity level. Motor evoked potentials will be recorded using surface electromyography. Input-output curves will be modeled using a Boltzmann sigmoidal function, and the slope, plateau, and S50 parameters will be extracted. The outcome will be expressed as the change in these input-output curve parameters from pre- to post-application of topical capsaicin cream.
At baseline (before capsaicin cream application); at pain stabilization (after capsaicin cream application)

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Kipukatastrofointi liittyen kipuun
Aikaikkuna: Perustaso
Kipukatastrofointia arvioidaan käyttäen ranskalais-kanadalaista versiota Kipukatastrofointiasteikosta (PCS-CF), joka on itsearviointikysely, jonka tarkoituksena on mitata kipuun liittyviä katastrofiajatuksia. PCS-CF sisältää 13 kohdetta, jotka arvioidaan Likert-asteikolla arvoilla 0 ("ei lainkaan") - 4 ("koko ajan"), kattaen kolme ulottuvuutta: pakkomielteinen miettiminen, suurentelu ja avuttomuus. Koepistelaskut lasketaan yhteen, jolloin saadaan kokonaispistemäärä väliltä 0-52, jossa korkeammat pisteet osoittavat suurempaa kipukatastrofointia. Kokonaispistemäärää ≥30 on ehdotettu käytettäväksi kliinisesti merkittävän kipukatastrofoinnin tasojen tunnistamiseen.
Perustaso
Kinesiophobia
Aikaikkuna: Baseline
Kinesiophobia will be assessed using the French-Canadian version of the Tampa Kinesiophobia Questionnaire (EKT-CF). It takes the form of a self-reported questionnaire of 17 items using a Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree), with an acceptable degree of internal consistency (Cronbach's alpha = 0.71), satisfactory construct validity, and high sensitivity to change (intra-class correlation coefficient > 0.7). The total score is obtained by adding the value of the responses and is between 17 and 68. The value of 37/68 is considered as the threshold value at which kinesiophobia becomes significant.
Baseline

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Päätutkija: Guillaume Léonard, Ph.D., Université de Sherbrooke

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Lauantai 1. elokuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Maanantai 30. marraskuuta 2026

Opintojen valmistuminen (Arvioitu)

Torstai 31. joulukuuta 2026

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 25. kesäkuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Torstai 2. heinäkuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Tiistai 7. heinäkuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 7. heinäkuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Torstai 2. heinäkuuta 2026

Viimeksi vahvistettu

Keskiviikko 1. heinäkuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa